PDGFRA and hepatocellular carcinoma: Thus, these results indicate that regardless of high PDGFRA expression or LR, avapritinib potently enhanced the sensitivity of these HCC cells to lenvatinib, thereby exhibiting a significant synergistic inhibitory effect.